{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:11:32Z","timestamp":1785255092337,"version":"3.55.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ahj.2020.04.025","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T19:55:47Z","timestamp":1588535747000},"page":"29-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["A current review of COVID-19 for the cardiovascular specialist"],"prefix":"10.1016","volume":"226","author":[{"given":"Joshua P.","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe A.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan K.","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"Bohula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.04.025_bb0005","author":"The Johns Hopkins Coronavirus Resource Center"},{"key":"10.1016\/j.ahj.2020.04.025_bb0010","series-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan","author":"Shi","year":"2020"},{"issue":"11","key":"10.1016\/j.ahj.2020.04.025_bb0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan","volume":"323","author":"Wang","year":"2020","journal-title":"China JAMA"},{"issue":"10229","key":"10.1016\/j.ahj.2020.04.025_bb0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ahj.2020.04.025_bb0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.2020.0757","article-title":"Coronavirus infections\u2014more than just the common cold","volume":"323","author":"Paules","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.04.025_bb0030","unstructured":"Centers for Disease Control and Prevention. In the absence of SARS-CoV transmission worldwide: guidance for surveillance, clinical and laboratory evaluation, and reporting. 2005. https:\/\/www.cdc.gov\/sars\/surveillance\/absence.html. Accessed 02 April 2020."},{"key":"10.1016\/j.ahj.2020.04.025_bb0035","unstructured":"Centers for Disease Control and Prevention. MERS clinical features. 2019. https:\/\/www.cdc.gov\/coronavirus\/mers\/clinical-features.html. Accessed 02 April 2020."},{"key":"10.1016\/j.ahj.2020.04.025_bb0040","article-title":"COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies","volume":"443","author":"Atri","year":"2020","journal-title":"JACC: Basic to Translational Science"},{"key":"10.1016\/j.ahj.2020.04.025_bb0045","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Kleine-Weber H, Kr\u00fcger N, M\u00fcller M, Drosten C, P\u00f6hlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv 2020:2020.01.31.929042.","DOI":"10.1101\/2020.01.31.929042"},{"key":"10.1016\/j.ahj.2020.04.025_bb0050","unstructured":"Centers for Disease Control and Prevention. How coronavirus spreads. 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/prepare\/transmission.html. Accessed 02 April 2020."},{"issue":"16","key":"10.1016\/j.ahj.2020.04.025_bb0055","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2020.3227","article-title":"Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient","volume":"323","author":"Ong","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ahj.2020.04.025_bb0060","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.02.055","article-title":"Evidence for gastrointestinal infection of SARS-CoV-2","volume":"158","author":"Xiao","year":"2020","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.ahj.2020.04.025_bb0065","first-page":"1843","article-title":"Detection of SARS-CoV-2 in different types of clinical specimens","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"issue":"6490","key":"10.1016\/j.ahj.2020.04.025_bb0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1126\/science.abb3221","article-title":"Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)","volume":"368","author":"Li","year":"2020","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.ahj.2020.04.025_bb0075","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMc2004973","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1","volume":"382","author":"van Doremalen","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2020.04.025_bb0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.15585\/mmwr.mm6912e3","article-title":"Public health responses to COVID-19 outbreaks on cruise ships\u2014worldwide, February-March 2020","volume":"69","author":"Moriarty","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ahj.2020.04.025_bb0085","unstructured":"Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant"},{"key":"10.1016\/j.ahj.2020.04.025_bb0090","unstructured":"Chinese Center for Disease Control and Prevention. Tracking the epidemic\u2014National Health Commission update. 2020. http:\/\/weekly.chinacdc.cn\/news\/TrackingtheEpidemic.htm. Accessed 02 April 2020."},{"key":"10.1016\/j.ahj.2020.04.025_bb0095","doi-asserted-by":"crossref","unstructured":"Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Internal Medicine 2020.","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"10.1016\/j.ahj.2020.04.025_bb0100","unstructured":"Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine 2020."},{"issue":"1","key":"10.1016\/j.ahj.2020.04.025_bb0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MNH.0b013e328341164a","article-title":"Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease","volume":"20","author":"Tikellis","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ahj.2020.04.025_bb0110","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1038\/ncomms4594","article-title":"Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ahj.2020.04.025_bb0115","unstructured":"HFSA\/ACC\/AHA. HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed 02 April 2020."},{"key":"10.1016\/j.ahj.2020.04.025_bb0120","unstructured":"European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020. Accessed 02 April 2020."},{"issue":"17","key":"10.1016\/j.ahj.2020.04.025_bb0125","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2020.04.025_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2020.04.025_bb0135","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2009020","article-title":"ST-segment elevation in patients with Covid-19\u2014a case series","author":"Bangalore","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.ahj.2020.04.025_bb0140","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/eurheartj\/ehq456","article-title":"Troponin elevation in coronary vs. non-coronary disease","volume":"32","author":"Agewall","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.025_bb0145","doi-asserted-by":"crossref","unstructured":"Szerlip M, Anwaruddin S, Aronow HD, Cohen MG, Daniels MJ, Dehghani P, et al. Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) members and graduates. Catheterization and Cardiovascular Interventions 2020;n\/a(n\/a).","DOI":"10.1002\/ccd.28887"},{"key":"10.1016\/j.ahj.2020.04.025_bb0150","unstructured":"Fried Justin A, Ramasubbu K, Bhatt R, Topkara Veli K, Clerkin Kevin J, Horn E, et al. The variety of cardiovascular presentations of COVID-19. Circulation;0(0)."},{"issue":"4","key":"10.1016\/j.ahj.2020.04.025_bb0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1702090","article-title":"Acute myocardial infarction after laboratory-confirmed influenza infection","volume":"378","author":"Kwong","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2020.04.025_bb0160","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamacardio.2016.0433","article-title":"Seasonal influenza infections and cardiovascular disease mortality","volume":"1","author":"Nguyen","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2020.04.025_bb0165","article-title":"Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin","author":"Hu","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.025_bb0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1096","article-title":"Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)","author":"Inciardi","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"22","key":"10.1016\/j.ahj.2020.04.025_bb0175","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/archinte.166.22.2446","article-title":"Elevated cardiac troponin measurements in critically ill patients","volume":"166","author":"Lim","year":"2006","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.ahj.2020.04.025_bb0180","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1084\/jem.183.3.949","article-title":"Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum","volume":"183","author":"Kumar","year":"1996","journal-title":"J Exp Med"},{"issue":"9404","key":"10.1016\/j.ahj.2020.04.025_bb0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","article-title":"Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock","volume":"363","author":"Pathan","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ahj.2020.04.025_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/SHK.0000000000000261","article-title":"Dysregulation of intracellular calcium transporters in animal models of sepsis-induced cardiomyopathy","volume":"43","author":"Hobai","year":"2015","journal-title":"Shock"},{"key":"10.1016\/j.ahj.2020.04.025_bb0195","series-title":"First case of COVID-19 infection with fulminant myocarditis complication: case report and insights","author":"Zeng","year":"2020"},{"issue":"5","key":"10.1016\/j.ahj.2020.04.025_bb0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2020.04.025_bb0205","doi-asserted-by":"crossref","unstructured":"Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. European Journal of Heart Failure 2020;n\/a(n\/a).","DOI":"10.1002\/ejhf.1828"},{"issue":"19","key":"10.1016\/j.ahj.2020.04.025_bb0210","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/eurheartj\/ehaa286","article-title":"Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection","volume":"41","author":"Sala","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.025_bb0215","doi-asserted-by":"crossref","unstructured":"Zsuzsanna Varga AJF, Peter Steiger, Martina Haberecker, Rea Andermatt, Annelies S Zinkernagel, Mandeep R Mehra, Reto A Schuepbach, Frank Ruschitzka, Holger Moch. Endothelial cell infection and endotheliitis in COVID-19. The Lancet 2020.","DOI":"10.1016\/S0140-6736(20)30937-5"},{"key":"10.1016\/j.ahj.2020.04.025_bb0220","series-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan","author":"Ruan","year":"2020"},{"key":"10.1016\/j.ahj.2020.04.025_bb0225","unstructured":"Bartlett RH, Ogino MT, Brodie D, McMullan DM, Lorusso R, MacLaren G, et al. Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure. ASAIO Journal: Artificial Organ Research and Development 9000;Online First."},{"issue":"10","key":"10.1016\/j.ahj.2020.04.025_bb0230","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/jmv.23354","article-title":"Review: viral infections and mechanisms of thrombosis and bleeding","volume":"84","author":"Goeijenbier","year":"2012","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.ahj.2020.04.025_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/modpathol.3800247","article-title":"Pulmonary pathology of severe acute respiratory syndrome in Toronto","volume":"18","author":"Hwang","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ahj.2020.04.025_bb0240","series-title":"Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19)","author":"Luo","year":"2020"},{"issue":"5","key":"10.1016\/j.ahj.2020.04.025_bb0245","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S2352-3026(20)30109-5","article-title":"Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19","volume":"7","author":"Wang","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ahj.2020.04.025_bb0250","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.ahj.2020.04.025_bb0255","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/jth.14820","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1016\/j.ahj.2020.04.025_bb0260","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa030685","article-title":"A major outbreak of severe acute respiratory syndrome in Hong Kong","volume":"348","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.04.025_bb0265","doi-asserted-by":"crossref","unstructured":"Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. New England Journal of Medicine 2020:e38.","DOI":"10.1056\/NEJMc2007575"},{"key":"10.1016\/j.ahj.2020.04.025_bb0270","doi-asserted-by":"crossref","unstructured":"Gralinski LE, Bankhead A, 3rd, Jeng S, Menachery VD, Proll S, Belisle SE, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio 2013;4(4).","DOI":"10.1128\/mBio.00271-13"},{"issue":"22","key":"10.1016\/j.ahj.2020.04.025_bb0275","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ahj.2020.04.025_bb0280","unstructured":"Brigham and Women's Hospital. Brigham and Women's Hospital COVID-19 clinical guidelines. 2020. https:\/\/www.covidprotocols.org\/. Accessed 02 April 2020."},{"issue":"6","key":"10.1016\/j.ahj.2020.04.025_bb0285","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.ijcard.2013.01.274","article-title":"The cardiovascular manifestations of influenza: a systematic review","volume":"167","author":"Estabragh","year":"2013","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2020.04.025_bb0290","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"10.1016\/j.ahj.2020.04.025_bb0295","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.ahj.2020.04.025_bb0300","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","article-title":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease","volume":"141","author":"Clerkin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.025_bb0305","doi-asserted-by":"crossref","unstructured":"Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2020;n\/a(n\/a).","DOI":"10.1002\/phar.2398"},{"key":"10.1016\/j.ahj.2020.04.025_bb0310","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ahj.2020.04.025_bb0315","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.ahj.2020.04.025_bb0320","doi-asserted-by":"crossref","unstructured":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018;9(2).","DOI":"10.1128\/mBio.00221-18"},{"key":"10.1016\/j.ahj.2020.04.025_bb0325","series-title":"Feng JY","author":"Gordon","year":"2020"},{"issue":"12","key":"10.1016\/j.ahj.2020.04.025_bb0330","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.ahj.2020.04.025_bb0335","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2020.04.025_bb0340","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1016\/j.ahj.2020.04.025_bb0345","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.04.025_bb0350","unstructured":"The COVID-19 Investigation Team. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. 2020. https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.09.20032896v1.full.pdf. Accessed 02 April 2020."},{"issue":"3","key":"10.1016\/j.ahj.2020.04.025_bb0360","doi-asserted-by":"crossref","first-page":"105923","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for the 2019 novel coronavirus SARS-CoV-2","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ahj.2020.04.025_bb0365","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"105949","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ahj.2020.04.025_bb0370","doi-asserted-by":"crossref","unstructured":"Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020:2020.03.22.20040758.","DOI":"10.1101\/2020.03.22.20040758"},{"key":"10.1016\/j.ahj.2020.04.025_bb0375","unstructured":"American College of Cardiology. Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19. 2020. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/27\/14\/00\/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19. Accessed 02 April 2020."},{"key":"10.1016\/j.ahj.2020.04.025_bb0380","unstructured":"Borba MGS, Val FdA, Sampaio VS, Alexandre MAA, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv 2020:2020.04.07.20056424."},{"issue":"3","key":"10.1016\/j.ahj.2020.04.025_bb0385","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"15","key":"10.1016\/j.ahj.2020.04.025_bb0390","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","volume":"323","author":"Young","year":"2020","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.ahj.2020.04.025_bb0395","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.ahj.2020.04.025_bb0400","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell\u2013induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ahj.2020.04.025_bb0405","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virusres.2007.02.014","article-title":"Human immunopathogenesis of severe acute respiratory syndrome (SARS)","volume":"133","author":"Cameron","year":"2008","journal-title":"Virus Res"},{"issue":"Pt 12","key":"10.1016\/j.ahj.2020.04.025_bb0410","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1099\/vir.0.055533-0","article-title":"Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment","volume":"94","author":"Lau","year":"2013","journal-title":"J Gen Virol"},{"issue":"10223","key":"10.1016\/j.ahj.2020.04.025_bb0415","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ahj.2020.04.025_bb0420","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ahj.2020.04.025_bb0425","unstructured":"The Food and Drug Administration. Highlights of prescribing information\u2014tocilizumab package insert https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125276s114lbl.pdf. Accessed 18 April 2020."},{"key":"10.1016\/j.ahj.2020.04.025_bb0430","unstructured":"The Food and Drug Administration. Highlights of prescribing information\u2014sarilumab package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761037s000lbl.pdf. Accessed 18 April 2020."},{"issue":"1","key":"10.1016\/j.ahj.2020.04.025_bb0435","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ahj.2020.04.025_bb0440","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/civ395","article-title":"Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease","volume":"61","author":"Florescu","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.ahj.2020.04.025_bb0445","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2020.04.025_bb0450","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ahj.2020.04.025_bb0455","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"16","key":"10.1016\/j.ahj.2020.04.025_bb0460","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ahj.2020.04.025_bb0465","first-page":"854","article-title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)","volume":"46","author":"Alhazzani","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ahj.2020.04.025_bb0470","article-title":"Disruptive modifications to cardiac critical care delivery during the Covid-19 pandemic: an international perspective","volume":"27282","author":"Katz","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.04.025_bb0475","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4914","article-title":"Management of critically ill adults with COVID-19","author":"Poston","year":"2020","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.ahj.2020.04.025_bb0480","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.04.025_bb0485","unstructured":"Durvasula R, Wellington T, McNamara E, Watnick S. COVID-19 and kidney failure in the acute care setting: our experience from Seattle. Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2020.04.025_bb0490","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up","volume":"27284","author":"Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2020.04.025_bb0495","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/CIRCULATIONAHA.119.042960","article-title":"High-sensitivity cardiac troponin and the universal definition of myocardial infarction","volume":"141","author":"Chapman Andrew","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.025_bb0500","author":"Januzzi"},{"key":"10.1016\/j.ahj.2020.04.025_bb0505","unstructured":"American Society of Echocardiography. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak 2020. https:\/\/www.asecho.org\/ase-statement-covid-19\/? Accessed 17 April 2020."}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:04:06Z","timestamp":1757570646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320301332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":100,"alternative-id":["S0002870320301332"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.04.025","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A current review of COVID-19 for the cardiovascular specialist","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}